SELEXIPAG

SynDRA canonical compound SYN0007733 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	PTGIR
Mechanism of action	IP1 prostacyclin receptor agonist \| platelet aggregation inhibitor
Indication	pulmonary arterial hypertension (PAH)
Disease area	pulmonary

All known targets

uptravi
ACT-293987
NS-304
ACT293987
Uptravi
NS 304
ACT 293987
UNII-5EXC0E384L
Selexipag(NS-304)
5EXC0E384L
2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide
2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide
Selexipag [USAN:INN]
2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
Uptravi (TN)
CHEBI:90844
selexipagum
Uptravi Titration Pack
RefChem:58598
Selexipag TITRATION PACK
B01AC27
DTXCID501513526
MFCD10567093
NS-304;ACT-293987
C26H32N4O4S
Selexipag (Standard)
NS-304(Selexipag)
SELEXIPAG [INN]
SELEXIPAG [JAN]
SELEXIPAG [MI]
SELEXIPAG [USAN]
NS-304(Selexipag)?
SELEXIPAG [WHO-DD]
Selexipag (JAN/USAN/INN)
SCHEMBL674122
GTPL7552
orb1304415